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Traumatic brain injury (TBI) represents
one of the greatest unmet needs in
medicine and public health (Maas et al.,
2008). It is a major cause of death and
disability and leads to great personal suf-
fering to victims and relatives, as well as
huge direct and indirect costs to society
(Finkelstein et al., 2006; Faul et al., 2007;
Gustavsson et al., 2011). TBI is considered
“the most complex disease in our most
complex organ.” We now recognize that
TBI is not just an acute event but can
trigger a chronic process, with progressive
injury over hours, days, weeks, months,
and even years. The challenges posed by
TBI are huge.
Notwithstanding improved under-
standing of disease mechanisms, appro-
priate characterization of TBI is complex,
and even establishing a reliable diagnosis
in subjects with mild injuries, can be chal-
lenging. It remains difficult to “look into
the brain” and to track disease processes
on a continuous basis in vivo. Despite the
current availability of robust prognostic
models, estimates of outcome in individ-
ual patients often have a large confidence
interval. The emerging field of biomarkers
has great potential for improving charac-
terization of TBI: in the acute and subacute
phases, biomarkers can aid in the diagnosis
of TBI, in tracking disease processes and
for establishing more confident prognostic
estimates. In themore chronic phases, they
may indicate ongoing progressive damage
with neuronal and glial cell loss.
This special issue of Frontiers in
Neurology on biomarkers in brain injury
provides a comprehensive summary of our
current knowledge in the emerging field
of biomarkers across the TBI spectrum
from initial injury to long term outcome.
Despite the extremely promising results
presented, this issue also illustrates some
of the gaps in our knowledge, thus stim-
ulating further research and development.
Why, for example, is it so much more
difficult to find reliable serum biomark-
ers for brain injury than for, for example,
myocardial disease (e.g., troponin)? Could
this be perhaps that we still have insuffi-
cient knowledge of how degradation prod-
ucts from brain tissue are removed into
the venous blood? Is this directly into the
venous system, or indirectly by flow of the
extracellular fluid draining via the cere-
brospinal fluid into the sagittal sinus? Basic
understanding of such mechanisms would
be of great relevance toward optimal
biomarker sampling. Whilst many stud-
ies on the prognostic value of biomarkers
show clear prognostic effects, it should be
realized that numbers in these studies in
general are small and that the added value
of biomarkers as prognostic indicators
over and above other predictors has not
yet been adequately shown in multivari-
able analyses. The concept of being able
to differentiate between neuronal and glial
injury based upon biomarkers is excit-
ing. This topical issue will also address
relations between laboratory markers and
other biomarkers such as imaging modal-
ities. By definition characterization and
classification of brain injury is multidi-
mensional. Better characterization with
the aid of biomarkers can be expected
to facilitate Precision Medicine, a con-
cept recently advocated by the US National
Academy of Science (2011). Precision
Medicine aims for appropriate targeting
of management and individualizing treat-
ment approaches based upon more pre-
cise characterization of the disease process.
Achieving these goals and establishing the
role of biomarkers herein will require con-
firmation of promising results from proof
of concept studies in larger numbers. This
can best be accomplished in multidisci-
plinary, international collaborations, col-
lecting high quality prospective data in
observational studies in parallel to contin-
ued basic science research.
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